Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. The company's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women’s health. Myovant Sciences was established in 2016 and is based in Brisbane, California.

Pfizer

Myovant Sciences Ltd (NYSE: MYOV) stock is adding about one-fourth of its market capitalization Monday following a licensing deal with Pfizer Inc. (NYSE: PFE). What Happened: Myovant announced a collaboration with Pfizer to develop and commercialize relugolix for oncology indications and women's health in the U.S. and Canada.

Deal With Pfizer Sends Myovant Shares Higher: What Investors Need To Know

The shares of Myovant Sciences Ltd (NYSE:MYOV) are up 27.2% at $29.08 at last check, gapping to record highs, after the biopharmaceutical concern announced a collaboration with Pfizer (PFE) to develop and commercialize cancer treatment relugolix in both the U.S. and Canada.

Biopharmaceutical Stock Surges Thanks to Pfizer Partnership

Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada

UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

Shares of Myovant Sciences soared 16% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for men's and women's cancer in a deal worth up to $4.2 billion in upfront and potential milestone payments. Myovant will receive an upfront payment of $650 million to develop relugolix, a once-daily, oral gonadotropin-releasing hormone receptor antagonist for use in oncology and women's health in the U.S. and Canada.

Myovant shares soar 16% premarket on news of Pfizer cancer drug deal worth up to $4.2 billion

Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billionORGOVYX(relugolix) is the first approved therapy in the Sumitovant Biopharma family of companies Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billionORGOVYX(relugolix) is the first approved therapy in the Sumitovant Biopharma family of companies

Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women's health in the U.S. and Canada. Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

Riding strong data, Myovant recently secured FDA approval for relugolix in treating advanced prostate cancer. Under the brand Orgovyx, Myovant will market the said drug as soon as in January.

Myovant Sciences: Is The Ultimate Catalyst Coming?

•ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies •ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies

Sumitovant Biopharma Announces Myovant Sciences receives FDA Approval of ORGOVYXTM (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer

BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Administration (FDA) has approved ORGOVYX™ (relugolix) for the treatment of adult patients with advanced prostate cancer. ORGOVYX, which was granted Priority Review by the FDA, is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for men with advanced prostate cancer. The approval is based on efficacy and safety data from the Phase 3 HERO study of ORGOVYX in men with advanced prostate cancer. ORGOVYX is expected to be available in January 2021.

Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer

Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Myovant Sciences (MYOV) Stock?

BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:

Myovant Sciences to Present at Upcoming December Investor Conferences

Myovant Sciences' (MYOV) CEO Lynn Seely on Q2 2020 Results - Earnings Call Transcript

Shares of Myovant Sciences (NYSE:MYOV) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 5.06% over the past year to ($0.75), which missed the estimate of ($0.73).

Recap: Myovant Sciences Q2 Earnings

BASEL, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the second quarter fiscal year 2020.

Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020

As you know, Myovant's shares recently tumbled due to ambiguous Phase 3 data release for its prostate cancer franchise. Upon closer inspection, I believe that relugolix will ultimately be FDA-approved for prostate cancer.

Myovant Sciences: More Than Meets The Eye

Myovant has positive Phase 3 results in all 3 indications for its main drug relugolix. The stock has taken a huge dive based on disappointing results on a secondary endpoint of the relugolix Phase 3 prostate cancer trial.

The Sell-Off In Myovant Is Unjustified By Fundamentals

BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2020, ended September 30, 2020. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on November 12, 2020.

Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020

BASEL, Switzerland, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis and in women with uterine fibroids. The data were presented in virtual oral and poster sessions during the American Society for Reproductive Medicine (ASRM) 2020 Virtual Congress, held October 17-21, 2020.

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids

Myovant: Relugolix Has Strong Competition

BASEL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan Crowe as vice president, investor relations. In addition to managing day-to-day interactions with analysts and investors, Mr. Crowe will be responsible for developing and implementing a comprehensive and strategic global investor relations program. He will report to Frank Karbe, Myovant’s president and chief financial officer.

Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations

Myovant Sciences posted poor trial data for part of a Phase 3 study for a prostate cancer treatment that awaits key FDA action later this year, and MYOV stock plummeted out of a buy zone.
The post Myovant Sciences Stock Crashes On Poor Trial Data For Prostate Cancer Treatment appeared first on Investor's Business Daily.

Myovant Sciences Stock Crashes On Poor Trial Data For Prostate Cancer Treatment

Atlanta, Georgia--(Newsfile Corp. - September 29, 2020) -  Holzer & Holzer, LLC is investigating whether Myovant Sciences Ltd. (NYSE: MYOV)  ("Myovant" or the "Company") complied with federal securities laws.  On September 29, 2020, the Company announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer. The price of Myovant's stock fell following the announcement. If you purchased shares of Myovant and...

SHAREHOLDER ALERT: Investigation of Myovant Announced by Holzer & Holzer, LLC

BASEL, Switzerland, Sept.  29, 2020  (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer. Relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks.

Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer

BASEL, Switzerland, Sept.  23, 2020  (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S. Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000.

Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

Adaptimmune Therapeutics

Chemocentryx

Kodiak Sciences Inc

Seres Therapeutics

Novavax

Sorrento Therapeutics Inc

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

News for Myovant Sciences Stock (MYOV)